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Abstract: A library of approximately 2000 small molecules biased
toward inhibition of histone deacetylases was assayed for antimalarial
activity in a high-throughput P. falciparum viability assay. Active
compounds were cross-analyzed for induction of histone hyperacety-
lation in a human myeloma cell line to identify HDAC inhibitors with
selectivity for P. falciparum over the human host. To verify on-target
selectivity, pfHDAC-1 was expressed and puriﬁed and a biochemical
assay for pfHDAC-1 activity was established.
The overwhelming majority of morbidity and mortality
associated with human malaria is caused by the apicomplexan
parasite Plasmodium falciparum. Widespread resistance to
mainstay therapies such as chloroquine,
1 atovaquone,
2 py-
rimethamine,
3 and sulfadoxine
4 has highlighted the need for new
drugs. In addition to problems with resistance, the current suite
of approved antimalarial drugs is limited to only a few targets
within the parasite. Here, we address this issue through the
identiﬁcation and characterization of P. falciparum histone
deactylase-1 (pfHDAC-1
a) inhibitors that are potent against
cultured parasite strains but do not perturb mammalian histone
acetylation.
The histone epigenetic code is a key regulator of eukaryotic
gene expression.
5 The reversible acetylation of lysine residues
within histone tails is regulated by histone acetyltransferase
(HAT) and histone deacetylase (HDAC) activity. HATs catalyze
the acetylation of histone tails causing localized relaxation of
chromatin and transcriptional activation of nearby genes, while
HDACs catalyze the deacetylation of acetylated histones leading
to transcriptional repression.
6 Equilibrium between the activities
of HATs and HDACs must be maintained for proper transcrip-
tional activity and cellular function. Mammalian HDACs are
divided into four major classes based on size, cellular localiza-
tion, catalytic domain, sequence homology, and mechanism of
action. Classes I, II, and IV are zinc-dependent hydrolases,
whereas class III enzymes, also called sirtuins, form an unrelated
NAD-dependent subfamily. Class I HDACs are generally
located in the nucleus and are relatively small in size; class II
HDACs are present in the nucleus and cytoplasm and are
generally larger.
7
Disregulation of HDAC activity is an important therapeutic
target. For example, HDAC inhibition has been shown to repress
the transcription of tumor suppressor genes associated with the
progression of various leukemias.
8,9 The activity of class I and
II HDACs can be inhibited by binding the zinc-containing
tubular pocket of the enzyme.
10 These inhibitors can be classiﬁed
into several groups: short-chain fatty acids such as butyrate and
valproic acid; hydroxamates such as trichostatin A 3 (TSA),
suberoylanilide hydroxamic acid 4 (SAHA), and LBH-589 5;
benzamides such as MS-275 6; cyclic tetrapetides such as
apicidin 7; and electrophilic ketones such as triﬂuoromethylke-
tones.
8,11 4, the most thoroughly characterized of these inhibi-
tors, was recently approved by the Food and Drug Administra-
tion for the treatment of cutaneous T-cell lymphoma.
12 Although
4 is an effective HDAC inhibitor, it shows little species or
isoform selectivity. Selective inhibition of speciﬁc HDACs can
be achieved by structural modiﬁcation of the recognition cap
or metal-chelating functional group that is characteristic of most
known HDAC inhibitors.
13
Targeting of HDACs in apicomplexan protozoans, including
the malaria parasite, has been previously investigated for drug
discovery and development.
14,15 The malaria parasite undergoes
signiﬁcant morphological changes during its asexual life cycle
in humans and during transmission from the insect vector to
the human host, and appropriate control of histone acetylation
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Figure 1. HDAC-biased chemical library. The archetypal HDAC
inhibitor, and the basis for this focused library, consists of a capping
element joined to a metal chelating moiety by a hydrophobic linker.
Diversity was introduced at all three of these motifs with the ﬁnal library
consisting of ∼2000 chemical members.
Table 1. Substrate-Speciﬁcity of pfHDAC-1
substrate Km
app (µM) kcat (s-1)
Ac-Leu-Gly-Lys(Ac)-AMC 1 30 ( 2 0.19 ( 0.01
Boc-Lys(triﬂuoroacetyl)-AMC 2 NA
a NA
a No activity observed with 2 in the presence of excess substrate and
pfHDAC-1.
Table 2. Inhibition of pfHDAC-1 Activity and P. falciparum 3D7
Proliferation by Known HDAC Inhibitors
IC50 (nM)
compd pfHDAC-1 P. falciparum 3D7
3 0.6 ( 0.1 16 ( 7
4 59 ( 6 210 ( 30
5 1.8 ( 0.2 21 ( 3
6 940 ( 90 >10000
7 1 ( 0.1 33 ( 5
splitomicin >10000 >10000
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7, which elicits an increase in P. falciparum histone acetylation
concomitant with reduced parasite proliferation, provided the
initial proof of concept for the essentiality of HDAC function
in the parasite.
16 Unfortunately, unfavorable pharmacological
properties limited the further development of 7 as an antimalarial
agent.
Genome sequencing of Plasmodium falciparum uncovered
one class I HDAC, two class II HDACs, and two class III
sirtuins. Only one of the class III enzymes, P. falciparum silent
information regulator 2 (pfSir2; PlasmoDB gene ID, PF13_0152),
has been deﬁnitively shown to possess HDAC activity.
17,18 The
putative class I and II HDACs have not yet been examined in
sufﬁcient detail to conﬁrm actual HDAC activity. Expression
and puriﬁcation of class I HDACs have generally afforded
greater success than the class II enzymes, and thus, we focused
our study on the sole class I HDAC, pfHDAC-1 (PlasmoDB
gene ID, PFI1260c). The enzyme is a 51 kDa nuclear protein
that is expressed in gametocytes and mature blood stages of
the malaria parasite life cycle and shares signiﬁcant homology
to all of the class I human HDACs.
19
I. For expression and puriﬁcation of pfHDAC-1, pfHDAC-1
was recombinantly expressed and puriﬁed from S2 insect cells.
The cDNA encoding the PfHDAC-1 was shuttled into the
pAc5.1 expression vector using Gateway cloning (Invitrogen)
with an engineered HPC4 epitope tag at the C-terminus for
puriﬁcation. S2 cells were co-transfected with this vector plus
pCoBlast (Invitrogen), and a stable pool of transfectants was
generated using blasticidin as the selective antibiotic.
II. For biochemical characterization of recombinant pfHDAC-
1, the endogenous histone substrate from P. falciparum is not
conveniently available to perform a detailed kinetic analysis of
pfHDAC-1. Therefore, we investigated the possibility of
measuring enzyme activity using a series of artiﬁcial substrates
that resemble an N-acetylated lysine residue and that have been
demonstrated to be processed by mammalian and bacterial class
I or class II HDACs.
20,21
Of the two substrates that were examined for recognition by
pfHDAC-1 only 1 was efﬁciently catalyzed (Table 1). The
Michaelis-Menten model was ﬁtted to the data which afforded
the kinetic constants kcat,1 ) 0.19 ( 0.01 s-1 and Km,1
app ) 30
( 2 µM. The binding afﬁnity and catalytic efﬁciency of 1 to
pfHDAC-1 are comparable to those observed with class I
HDACs from other organisms. The known HDAC inhibitors
3-7 were tested for the inhibition of pfHDAC-1 activity and
parasite proliferation (Table 2). 3-5 and 7 were found to be
inhibitory in both assays, whereas 6 did not demonstrate
signiﬁcant inhibition of either pfHDAC-1 activity or parasite
growth. Interestingly, o-aminoanilide based compounds such as
6 have been documented to exhibit selectivity for human class
I over class II enzymes.
22 The class III speciﬁc HDAC inhibitor
splitomicin was also determined to be inactive in enzyme and
parasite inhibition assays.
III. For inhibition of pfHDAC-1 and parasite proliferation,
the archetypal chemical structure for a HDAC inhibitor consists
of a metal chelating group joined by a carbon chain linker to a
hydrophobic capping element that confers potency and selectiv-
ity (Figure 1).
23
Given the effectiveness of hydroxamate-based HDAC inhibi-
tors, it was hypothesized that selectivity could be engineered
for pfHDAC-1 and the malaria parasite with a core scaffold
containing a hydroxamate metal chelating unit. Although not
species selective, the spectrum of activity already observed for
3-5 supported this model (Table 2). For this reason, a ∼2000
member HDAC-biased chemical library was sequentially screened
for antimalarial efﬁcacy and inhibition of pfHDAC-1 activity.
Chemical diversity within the library was introduced at the
recognition cap or metal chelating portion of the molecule, and
the linker length between these two groups was varied from
four to six carbons (Figure 1).
24
We have previously analyzed this library for the alteration
of in vivo bulk histone acetylation in mammalian cells (Sup-
porting Information Figure 1). Many compounds were found
to potently inhibit parasite proliferation and pfHDAC-1 activity;
however, only 17 displayed antiparasitic activity coupled with
minimal perturbation of mammalian histone acetylation (Table
3). Inhibition of P. falciparum proliferation was biased toward
compounds with ortho-substitution (bromine, hydroxyl) in the
cap region of the core scaffold.
The presence of a hydroxamic acid as a metal chelating ligand
was necessary for activity. The ideal linker length for selective
compounds was found to be ﬁve methylene units in contrast to
the six methylene units preferred for compounds inducing
histone hyperacetylation in mammalian cells.
Table 3. Inhibition of P. falciparum Growth and pfHDAC-1 Activity by Cherry-Picked Hits from the HDAC-Biased Chemical Library
compd R n pfHDAC-1, IC50 (nM)
fold change in MM.1S
histone acetylation
a
P. falciparum
3D7, IC50 (nM)
8 3-hydroxyphenyl 5 59 ( 6 1.2 99 ( 12
9 2,5-dihydroxyphenyl 6 110 ( 13 1.1 142 ( 28
10 6-bromobenzo[d][1,3]dioxol-5-yl 5 20 ( 2 1.0 59 ( 15
11 2,4,6-trishydroxyphenyl 6 43 ( 5 1.1 50 ( 6
12 2-bromo-5-methoxyphenyl 5 22 ( 2 1.1 >500
13 4-(dimethylamino)-2-hydroxyphenyl 5 37 ( 4 1.2 24 ( 2
14 2-hydroxynaphthalen-1-yl 5 41 ( 4 1.0 20 ( 2
15 2-bromo-5-hydroxyphenyl 5 49 ( 5 1.0 35 ( 4
16 2-bromophenyl 5 37 ( 4 1.1 15 ( 2
17 2-bromo-4-hydroxy-5-methoxyphenyl 5 59 ( 7 1.0 47 ( 7
18 2-chlorophenyl 5 90 ( 10 0.9 288 ( 20
19 4-(1H-imidazol-1-yl)phenyl 5 15 ( 2 1.0 57 ( 11
20 2-bromopyridin-3-yl 5 36 ( 6 0.9 22 ( 5
21 2-bromo-4-hydroxyphenyl 4 106 ( 11 1.1 53 ( 13
22 2-bromo-5-hydroxyphenyl 4 89 ( 9 1.1 30 ( 7
23 2-bromo-4-hydroxy-5-methoxyphenyl 4 59 ( 5 1.2 498 ( 168
24 4-boronophenyl 4 45 ( 5 1.0 68 ( 8
a The fold change in MM.1S histone acetylation was measured at a compound concentration of 0.2 µM.
2186 Journal of Medicinal Chemistry, 2009, Vol. 52, No. 8 LettersTranscriptional regulation orchestrates the multiple morpho-
logical transformations that occur throughout the complex
developmental stages of the P. falciparum life cycle. HDACs
participate in the reversible acetylation of lysine residues within
histone tails to control chromatin unwinding and DNA tran-
scription. Inhibition of HDAC activity has already proven useful
for the treatment of various cancers and may also be valuable
for the development of antimalarial chemotherapies. Here, we
have expressed recombinant pfHDAC-1, the sole class I isoform
identiﬁed by homology in P. falciparum, and conﬁrmed that
the protein has in vitro HDAC activity. The known HDAC
inhibitor 4 elicits hyperacetylation of P. falciparum histones
and retards parasite proliferation. Unfortunately 4 is neither
species nor HDAC-isoform selective, and yet speciﬁcity for
pfHDAC-1 and P. falciparum was obtained herein by modifying
the core scaffold. Seventeen compounds were found to signiﬁ-
cantly inhibit parasite proliferation and pfHDAC-1 activity, and
yet these compounds did not perturb histone acetylation or
inhibit whole-cell growth of mammalian MM.1S. These com-
pounds generally contained bromine and hydroxyl substituted
phenol derivatives as recognition caps and a hydroxamic acid
as the metal chelating ligand. It is noted that the mechanism of
action of these compounds is linked to pfHDAC-1 but is not
necessarily limited to this target. The compounds may, for
example, also target class II, other unidentiﬁed class I HDACs,
or possibly even other metalloenzymes in the parasite. Never-
theless, chemical optimization of these compounds including
replacement of the acyl hydrazone motive is underway for
improved pharmacological properties such as solubility and
serum stability. In vivo efﬁcacy trials using a murine malaria
model are planned for the near future.
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